Cinacalcet does not affect the pharmacokinetics or pharmacodynamics of warfarin

Drugs in R and D

Volumn 8, Issue 2, 2007, Pages 79-87

  Padhi, Desmond ^a,b   Sullivan, John T ^a  

^a AMGEN INC   (United States)

^b MS 38 3 A ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7; CINACALCET; PLACEBO; WARFARIN;

ABDOMINAL PAIN; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; ENANTIOMER; FATIGUE; FLATULENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; KIDNEY DISEASE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; POLLAKISURIA; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SINGLE DRUG DOSE; UPPER RESPIRATORY TRACT CONGESTION;

ADOLESCENT; ADULT; ANTICOAGULANTS; AREA UNDER CURVE; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NAPHTHALENES; PROTHROMBIN TIME; STEREOISOMERISM; WARFARIN;

EID: 33847354234     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200708020-00002     Document Type: Article

References (20)

1. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004 Aug; 15 (8): 2208-18
2. Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004 Apr; 350 (15): 1516-25
3. Lindberg JS, Culleton B, Wong G, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005 Mar; 16 (3): 800-7
4. Amgen Inc. Sensipar® (cinacalcet HCl) prescribing information [online]. Available from URL: http://www.sensipar.com/professional/ prescribing_information/prescribing_information.jsp [Accessed 2007 Feb12]
5. Wittkowsky AK. Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions. Semin Vasc Med 2003 Aug; 3 (3): 221-30
6. Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995 Jan; 47 (1): 186-92
7. Harnett JD, Foley RN, Kent GM, et al. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 1995 Mar; 47 (3): 884-90
8. Tveit DP, Hypolite IO, Hshieh P, et al. Chronic dialysis patients have high risk for pulmonary embolism. Am J Kidney Dis 2002 May; 39 (5): 1011-7
9. Peacock M, Bilezikian JP, Klassen PS, et al. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005 Jan; 90 (1): 135-41
10. Shoback DM, Bilezikian JP, Turner SA, et al. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 2003 Dec; 88 (12): 5644-9
11. Naidong W, Lee JW. Development and validation of a high-performance liquid chromatographic method for the quantitation of warfarin enantiomers in human plasma. J Pharm Biomed Anal 1993 Sep; 11 (9): 785-92
12. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987 Dec; 15 (6): 657-80
13. Center for Drug Evaluation and Research. Guidance for industry. In vivo drug metabolism/drug interaction studies - study design, data analysis and recommendations for dosing and labeling [online]. In: United States Department of Health and Human Services, Food and Drug Administration, November 1999. Available from URL: http://www.fda.gov/cder/guidance/2635fnl.pdf [Accessed 2007 Feb 7]
14. Sokal RR, Rohlf FJ. Biometry: the principles and practice of statistics in biological research. 3rd ed. San Francisco (CA): WH Freeman and Company, 1995
15. Charytan C, Coburn JW, Chonchol M, et al. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis 2005 Jul; 46 (1): 58-67
16. Tiseo PJ, Foley K, Friedhoff LT. The effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin. Br J Clin Pharmacol 1998 Nov; 46 Suppl. 1: 45-50
17. Kwan D, Bartle WR, Walker SE. The effects of acetaminophen on pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 1999 Jan; 39 (1): 68-75
18. Liao S, Palmer M, Fowler C, et al. Absence of an effect of levofloxacin on warfarin pharmacokinetics and anticoagulation in male volunteers. J Clin Pharmacol 1996 Nov; 36 (11): 1072-7
19. Van Hecken A, Depre M, Verbesselt R, et al. Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol 1999 May; 39 (5): 495-500
20. Priskorn M, Sidhu JS, Larsen F, et al. Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin. Br J Clin Pharmacol 1997 Aug; 44 (2): 199-202